In the analysis of clinical presentations, the expression of TP53 codon 72 polymorphism was increased in subgroups of tumor grade I, premenopausal status, distant metastases negative, distant metastases positive, while the expression of TP53 codon 72 polymorphism was decreased in the subgroups of PR-negative, tumor stage II, patients younger than 50 years and right localization. This evidence concerns the gene TP53 and neoplasm.